Zheng LP, et al. - Researchers conducted a single-arm, phase 2 clinical trial of EGFR-tyrosine kinase inhibitor (TKI) combined with thoracic radiotherapy as first-line therapy for stage IV non-small cell lung cancer (NSCLC) harboring EGFR active mutations. Until disease progression or intolerable adverse events (AEs), they administered EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54–60 Gy/27–30 F/5.5–6 w) to patients within 2 weeks of beginning EGFR-TKI therapy. Long-term control of the primary lung lesion was achieved in those treated with concurrent EGFR-TKI plus thoracic radiotherapy as first-line therapy. This combined therapy provided numerically higher 1-year progression-free survival (PFS) rate and median PFS vs the erlotinib monotherapy, with acceptable risk of serious AEs. Radiation pneumonitis and rash were the most commonly seen AEs.